Abstract
Superspreading is a ubiquitous feature of SARS-CoV-2 transmission dynamics, with a few primary infectors leading to a large proportion of secondary infections. Despite the superspreading events observed in previous coronavirus outbreaks, the mechanisms behind the phenomenon are still poorly understood. Here, we show that superspreading is largely driven by heterogeneity in contact behavior rather than heterogeneity in susceptibility or infectivity caused by biological factors. We find that highly heterogeneous contact behavior is required to produce the extreme superspreading estimated from recent COVID-19 outbreaks. However, we show that superspreading estimates are noisy and subject to biases in data collection and public health capacity, potentially leading to an overestimation of superspreading. These results suggest that superspreading for COVID-19 is substantial, but less than previously estimated. Our findings highlight the complexity inherent to quantitative measurement of epidemic dynamics and the necessity of robust theory to guide public health intervention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this publication was supported by the National Institute Of General Medical Sciences of the National Institutes of Health under Award Number R01GM123007. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study only uses de-identified published data from the literature, and thus IRB approval was not sought.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All simulation code, analysis code, and data are made available at https://github.com/zsusswein/COVID_superspreading.
